In a filing, Nektar Therapeutics revealed its Chief Legal Officer Wilson Mark Andrew unloaded Company’s shares for reported $30062.0 on Dec 23 ’24. In the deal valued at $0.90 per share,33,402 shares were sold. As a result of this transaction, Wilson Mark Andrew now holds 351,892 shares worth roughly $0.39 million.
Then, Wilson Mark Andrew sold 16,560 shares, generating $14,738 in total proceeds. Upon selling the shares at $0.89, the Chief Legal Officer now owns 335,332 shares.
Before that, Wilson Mark Andrew bought 16,560 shares. Nektar Therapeutics shares valued at $14,801 were divested by the Officer at a price of $0.89 per share.
H.C. Wainwright initiated its Nektar Therapeutics [NKTR] rating to a Buy in a research note published on December 10, 2024; the price target was $6.50. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Rodman & Renshaw started covering the stock on June 28, 2024. It rated NKTR as “a Buy”.
Price Performance Review of NKTR
On Friday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock jump 14.46% to $1.10. Over the last five days, the stock has gained 15.64%. Nektar Therapeutics shares have risen nearly 18.28% since the year began. Nevertheless, the stocks have risen 97.49% over the past one year. While a 52-week high of $1.93 was reached on 01/03/25, a 52-week low of $0.48 was recorded on 01/02/25. SMA at 50 days reached $1.1170, while 200 days put it at $1.2673.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 0.9867, which if violated will result in even more drops to 0.8733. On the upside, there is a resistance level at 1.1867. A further resistance level may holdings at 1.2733. The Relative Strength Index (RSI) on the 14-day chart is 59.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0350, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 20.70%. Stochastics %K at 54.38% indicates the stock is a holding.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2024-12-13, dropping by -0.73 million shares to a total of 4.4 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 5.13 million shares. There was a decline of -16.59%, which implies that there is a negative sentiment for the stock.
